ANSWER Cohort

Back

Articles

2021


Drug efficacy and safety of biologics and Janus kinase inhibitors in elderly patients with rheumatoid arthritis
Kosuke Ebina
Modern Rheumatology, roab003, https://doi.org/10.1093/mr/roab003, 04 September 2021. Journal Link

Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
Maeda Y, Hirano T, Ebina K, Hara R, Hashimoto M, Yamamoto W, Murakami K, Kotani T, Hata K, Son Y, Amuro H, Onishi A, Jinno S, Katayama M, Kumanogoh A
Rheumatol Int. 2021 Jul;41(7):1233-1241. doi: 10.1007/s00296-021-04862-y. Epub 2021 Apr 26. Pubmed

Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Onishi A, Jinno S, Hara R, Son Y, Amuro H, Takeuchi T, Yoshikawa A, Katayama M, Yamamoto K, Hirao M, Okita Y, Kumanogoh A, Nakata K.
Clin Rheumatol. 2021 Jul;40(7):2673-2680. doi: 10.1007/s10067-021-05609-7. Pubmed

Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.
Jinno S, Onishi A, Dubreuil M, Hashimoto M, Yamamoto W, Murata K, Takeuchi T, Kotani T, Maeda Y, Ebina K, Son Y, Amuro H, Hara R, Katayama M, Saegusa J.
Arthritis Res Ther. 2021 Apr 15;23(1):116. doi: 10.1186/s13075-021-02496-w. Pubmed

The association of disease activity and estimated GFR in patients with rheumatoid arthritis: findings from the ANSWER Study.
Onishi A, Akashi K, Yamamoto W, Ebina K, Murata K, Hara R, Katayama M, Nagai K, Hirano T, Amuro H, Son Y, Yamamoto K, Hashimoto M, Morinobu A
Am J Kidney Dis. 2021 May 10;S0272-6386(21)00577-1. doi: 10.1053/j.ajkd.2021.02.338. Pubmed

2020


Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study
Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W, Murata K, Takeuchi T, Kotani T, Maeda Y, Ebina K, Son Y, Amuro H, Hara R, Katayama M, Saegusa J, Morinobu A.
Rheumatol Int. 2020 Dec;40(12):1987-1995. doi: 10.1007/s00296-020-04660-y. Pubmed

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Shiba H, Son Y, Amuro H, Onishi A, Akashi K, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M.
Arthritis Res Ther. 2020 Jun 15;22(1):142. doi: 10.1186/s13075-020-02232-w. Pubmed

Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K, Takeuchi T, Nagai K, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Katayama M, Yamamoto K, Kumanogoh A, Hirao M.
Clin Rheumatol. 2020 Mar 11. doi: 10.1007/s10067-020-05015-5. Pubmed

2019


The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study.
Murata K, Hashimoto M, Yamamoto W, Son Y, Amuro H, Nagai K, Takeuchi T, Katayama M, Maeda Y, Ebina K, Hara R, Jinno S, Onishi A, Murakami K, Tanaka M, Ito H, Mimori T, Matsuda S.
Rheumatol Int. 2020 Feb;40(2):217-225. doi: 10.1007/s00296-019-04464-9. Epub 2019 Oct 16. Pubmed

Clinical Course of Amyloid A Amyloidosis Secondary to Rheumatoid Arthritis Treated with Anti-Rheumatic Drugs Including Biologic Agent: Case Series in Answer Cohort.
Hirano T, Maeda Y, Ebina K, Nagai K, Son Y, Amuro H, Hara R, Hashimoto M, Kumanogoh A.
Archives of Clinical and Medical Case Reports 3 (2019): 508-517. Journal Link

Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.
PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019. Journal Link Pubmed

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Hirano T, Hara R, Katayama M, Onishi A, Nagai K, Son Y, Amuro H, Yamamoto K, Maeda Y, Murata K, Jinno S, Takeuchi T, Hirao M, Kumanogoh A, Yoshikawa H.
Arthritis Res Ther. 2019 Apr 11;21(1):91. doi: 10.1186/s13075-019-1880-4. Erratum in: Arthritis Res Ther. 2019 May 6;21(1):114. Jounal Link Pubmed

2018


Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, Ohnishi A, Akashi K, Yoshida S, Nagai K, Son Y, Amuro H, Hirano T, Ebina K, Uozumi R, Ito H, Tanaka M, Ohmura K, Fujii T, Mimori T.
Arthritis Res Ther. 2018 Aug 3;20(1):165. doi: 10.1186/s13075-018-1673-1. Journal Link Pubmed

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K, Shintani A, Kumanogoh A, Yoshikawa H.
PLoS One. 2018 Mar 15;13(3):e0194130. doi: 10.1371/journal.pone.0194130. eCollection 2018. Journal Link Pubmed

Copyright © ANSWER Cohort Consortium All Rights Reserved.